APOBEC3G Polymorphism as a Selective Barrier to Cross-Species Transmission and Emergence of Pathogenic SIV and AIDS in a Primate Host

PLoS Pathogens

Volumn 9, Issue 10, 2013, Pages

  Krupp, Annabel ^a,b   McCarthy, Kevin R ^c   Ooms, Marcel ^d   Letko, Michael ^d   Morgan, Jennifer S ^b   Simon, Viviana ^d   Johnson, Welkin E ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b BOSTON COLLEGE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; VIF PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; ANIMAL CELL; ARTICLE; CERCOCEBUS; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN DEGRADATION; RHESUS MONKEY; SEQUENCE ALIGNMENT; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS RESISTANCE; VIRUS TRANSMISSION; WESTERN BLOTTING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; CERCOCEBUS ATYS; CERCOPITHECUS AETHIOPS; CYTIDINE DEAMINASE; HELA CELLS; HUMANS; MACACA; POLYMORPHISM, GENETIC; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SPECIES SPECIFICITY;

EID: 84887279415     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003641     Document Type: Article

References (76)

1. VandeWoude S, Apetrei C, (2006) Going wild: lessons from naturally occurring T-lymphotropic lentiviruses. Clinical microbiology reviews 19: 728-762.
2. Sharp PM, Hahn BH, (2011) Origins of HIV and the AIDS pandemic. Cold Spring Harbor perspectives in medicine 1: a006841.
3. Charleston MA, Robertson DL, (2002) Preferential host switching by primate lentiviruses can account for phylogenetic similarity with the primate phylogeny. Systematic biology 51: 528-535.
4. Hahn BH, Shaw GM, De Cock KM, Sharp PM, (2000) AIDS as a zoonosis: scientific and public health implications. Science 287: 607-614.
5. Apetrei C, Robertson DL, Marx PA, (2004) The history of SIVS and AIDS: epidemiology, phylogeny and biology of isolates from naturally SIV infected non-human primates (NHP) in Africa. Frontiers in bioscience: a journal and virtual library 9: 225-254.
6. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, et al. (2006) Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313: 523-526.
7. Mansfield KG, Lerche NW, Gardner MB, Lackner AA, (1995) Origins of Simian Immunodeficiency Virus-Infection in Macaques at the New-England-Regional-Primate-Research-Center. Journal of medical primatology 24: 116-122.
8. Gardner MB, (2003) Simian AIDS: an historical perspective. Journal of medical primatology 32: 180-186.
9. Apetrei C, Lerche NW, Pandrea I, Gormus B, Silvestri G, et al. (2006) Kuru experiments triggered the emergence of pathogenic SIVmac. AIDS 20: 317-321.
10. Bieniasz PD, (2004) Intrinsic immunity: a front-line defense against viral attack. Nature immunology 5: 1109-1115.
11. Yan N, Chen ZJ, (2012) Intrinsic antiviral immunity. Nature immunology 13: 214-222.
12. Meyerson NR, Sawyer SL, (2011) Two-stepping through time: mammals and viruses. Trends in microbiology 19: 286-294.
13. Patel MR, Emerman M, Malik HS, (2011) Paleovirology- ghosts and gifts of viruses past. Current opinion in virology 1: 304-309.
14. Johnson WE (2013) Rapid Adversarial Co-Evolution of Viruses and Cellular Restriction Factors. In: Cullen BR, editor. Intrinsic Immunity, Current Topics in Microbiology and Immunology. Berlin Heidelberg: Springer-Verlag.
15. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, et al. (2010) TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS biology 8: e1000462.
16. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
17. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
18. Malim MH, (2009) APOBEC proteins and intrinsic resistance to HIV-1 infection. Philosophical transactions of the Royal Society of London Series B, Biological sciences 364: 675-687.
19. Chiu Y-L, Greene WC, (2008) The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements. Annual review of immunology 26: 317-353.
20. Harris RS, Liddament MT, (2004) Retroviral restriction by APOBEC proteins. Nature reviews Immunology 4: 868-877.
21. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, et al. (2009) Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. Journal of virology 83: 9474-9485.
22. Goila-Gaur R, Strebel K, (2008) HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5: 51.
23. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, et al. (2003) Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif. Cell 114: 21-31.
24. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR, (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proceedings of the National Academy of Sciences of the United States of America 101: 3770-3774.
25. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, et al. (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proceedings of the National Academy of Sciences of the United States of America 101: 5652-5657.
26. Desrosiers RC, (1990) The simian immunodeficiency viruses. Annual review of immunology 8: 557-578.
27. Hatziioannou T, Evans DT, (2012) Animal models for HIV/AIDS research. Nature reviews Microbiology 10: 852-867.
28. Schrofelbauer B, Chen D, Landau NR, (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proceedings of the National Academy of Sciences of the United States of America 101: 3927-3932.
29. Mangeat B, Turelli P, Liao S, Trono D, (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. The Journal of biological chemistry 279: 14481-14483.
30. Hirsch V, Adger-Johnson D, Campbell B, Goldstein S, Brown C, et al. (1997) A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. Journal of virology 71: 1608-1620.
31. Compton AA, Hirsch VM, Emerman M, (2012) The host restriction factor APOBEC3G and retroviral Vif protein coevolve due to ongoing genetic conflict. Cell host & microbe 11: 91-98.
32. Compton AA, Emerman M, (2013) Convergence and Divergence in the Evolution of the APOBEC3G-Vif Interaction Reveal Ancient Origins of Simian Immunodeficiency Viruses. PLoS pathogens 9: e1003135.
33. Sawyer SL, Emerman M, Malik HS, (2004) Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS biology 2: E275.
34. Li J, Han K, Xing J, Kim HS, Rogers J, et al. (2009) Phylogeny of the macaques (Cercopithecidae: Macaca) based on Alu elements. Gene 448: 242-249.
35. Schrofelbauer B, Senger T, Manning G, Landau NR, (2006) Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. Journal of virology 80: 5984-5991.
36. Russell RA, Pathak VK, (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. Journal of virology 81: 8201-8210.
37. Chen G, He Z, Wang T, Xu R, Yu XF, (2009) A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. Journal of virology 83: 8674-8682.
38. Dang Y, Wang X, Zhou T, York IA, Zheng YH, (2009) Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. Journal of virology 83: 8544-8552.
39. Daniel MD, Letvin NL, King NW, Kannagi M, Sehgal PK, et al. (1985) Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 228: 1201-1204.
40. Kestler HW, 3rd, Li Y, Naidu YM, Butler CV, Ochs MF, et al. (1988) Comparison of simian immunodeficiency virus isolates. Nature 331: 619-622.
41. Daniel MD, Letvin NL, Sehgal PK, Schmidt DK, Silva DP, et al. (1988) Prevalence of antibodies to 3 retroviruses in a captive colony of macaque monkeys. International journal of cancer Journal international du cancer 41: 601-608.
42. Fischer W, Apetrei C, Santiago ML, Li Y, Gautam R, et al. (2012) Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages. Journal of virology 86: 13217-13231.
43. Novembre FJ, De Rosayro J, O'Neil SP, Anderson DC, Klumpp SA, et al. (1998) Isolation and characterization of a neuropathogenic simian immunodeficiency virus derived from a sooty mangabey. Journal of virology 72: 8841-8851.
44. Li W, Shi Z, Yu M, Ren W, Smith C, et al. (2005) Bats are natural reservoirs of SARS-like coronaviruses. Science 310: 676-679.
45. Dugan VG, Chen R, Spiro DJ, Sengamalay N, Zaborsky J, et al. (2008) The evolutionary genetics and emergence of avian influenza viruses in wild birds. PLoS pathogens 4: e1000076.
46. Cleaveland S, Haydon DT, Taylor L, (2007) Overviews of pathogen emergence: which pathogens emerge, when and why? Current topics in microbiology and immunology 315: 85-111.
47. Holmes EC, Drummond AJ, (2007) The evolutionary genetics of viral emergence. Current topics in microbiology and immunology 315: 51-66.
48. Neil S, Bieniasz P, (2009) Human immunodeficiency virus, restriction factors, and interferon. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 29: 569-580.
49. Harris RS, Hultquist JF, Evans DT, (2012) The restriction factors of human immunodeficiency virus. The Journal of biological chemistry 287: 40875-40883.
50. Blanco-Melo D, Venkatesh S, Bieniasz PD, (2012) Intrinsic cellular defenses against human immunodeficiency viruses. Immunity 37: 399-411.
51. Kirchhoff F, (2010) Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell host & microbe 8: 55-67.
52. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
53. Tokarev A, Skasko M, Fitzpatrick K, Guatelli J, (2009) Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS research and human retroviruses 25: 1197-1210.
54. Neil SJ, Zang T, Bieniasz PD, (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430.
55. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, et al. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell host & microbe 3: 245-252.
56. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, et al. (2011) SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474: 654-657.
57. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, et al. (2011) Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474: 658-661.
58. Kitamura S, Ode H, Nakashima M, Imahashi M, Naganawa Y, et al. (2012) The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nature structural & molecular biology 19: 1005-1010.
59. Kelley LA, Sternberg MJ, (2009) Protein structure prediction on the Web: a case study using the Phyre server. Nature protocols 4: 363-371.
60. Kitamura S, Ode H, Iwatani Y, (2011) Structural Features of Antiviral APOBEC3 Proteins are Linked to Their Functional Activities. Frontiers in microbiology 2: 258.
61. Vanderford TH, Demma LJ, Feinberg MB, Staprans SI, Logsdon JM Jr, (2007) Adaptation of a diverse simian immunodeficiency virus population to a new host is revealed through a systematic approach to identify amino acid sites under selection. Molecular biology and evolution 24: 660-669.
62. Meythaler M, Martinot A, Wang Z, Pryputniewicz S, Kasheta M, et al. (2009) Differential CD4+ T-lymphocyte apoptosis and bystander T-cell activation in rhesus macaques and sooty mangabeys during acute simian immunodeficiency virus infection. Journal of virology 83: 572-583.
63. Weiler A, May GE, Qi Y, Wilson N, Watkins DI, (2006) Polymorphisms in eight host genes associated with control of HIV replication do not mediate elite control of viral replication in SIV-infected Indian rhesus macaques. Immunogenetics 58: 1003-1009.
64. Luciw PA, Shaw KE, Unger RE, Planelles V, Stout MW, et al. (1992) Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). AIDS research and human retroviruses 8: 395-402.
65. Simon MA, Brodie SJ, Sasseville VG, Chalifoux LV, Desrosiers RC, et al. (1994) Immunopathogenesis of SIVmac. Virus research 32: 227-251.
66. Voss G, Hunsmann G, (1993) Cellular immune response to SIVmac and HIV-2 in macaques: model for the human HIV-1 infection. Journal of acquired immune deficiency syndromes 6: 969-976.
67. Gardner MB, (1990) SIV infection of macaques: a model for AIDS vaccine development. Developments in biological standardization 72: 259-266.
68. Lim SY, Chan T, Gelman RS, Whitney JB, O'Brien KL, et al. (2010) Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys. PLoS genetics 6: e1000997.
69. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC, (2009) Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. Journal of virology 83: 8289-8292.
70. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrobial agents and chemotherapy 46: 1896-1905.
71. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, et al. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. Journal of virology 74: 8358-8367.
72. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. Journal of virology 72: 2855-2864.
73. Higgins JR, Sutjipto S, Marx PA, Pedersen NC, (1992) Shared antigenic epitopes of the major core proteins of human and simian immunodeficiency virus isolates. Journal of medical primatology 21: 265-269.
74. Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AY, et al. (1998) Identification of highly attenuated mutants of simian immunodeficiency virus. Journal of virology 72: 1431-1437.
75. Mulder LC, Ooms M, Majdak S, Smedresman J, Linscheid C, et al. (2010) Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. Journal of virology 84: 9613-9617.
76. Simon V, Zennou V, Murray D, Huang Y, Ho DD, et al. (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS pathogens 1: e6.